Sensus Healthcare Inc
$ 2.70
-4.26%
05 Jun - close price
- Market Cap 44,447,600 USD
- Current Price $ 2.70
- High / Low $ 2.87 / 2.66
- Stock P/E N/A
- Book Value 2.92
- EPS -0.47
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.15 %
- 52 Week High 5.92
- 52 Week Low 2.66
About
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Analyst Target Price
$5.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-15 | 2025-02-05 | 2024-11-14 | 2024-08-08 | 2024-05-09 | 2024-02-08 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.16 | -0.19 | -0.06 | -0.06 | -0.16 | 0.09 | 0.07 | 0.1 | 0.14 | 0.26 | -0.09 | -0.02 |
| Estimated EPS | -0.11 | -0.05 | -0.11 | 0.01 | 0.02 | 0.12 | -0.01 | 0.03 | -0.04 | 0.14 | -0.02 | -0.08 |
| Surprise | -0.05 | -0.14 | 0.05 | -0.07 | -0.18 | -0.03 | 0.08 | 0.07 | 0.18 | 0.12 | -0.07 | 0.06 |
| Surprise Percentage | -45.4545% | -280% | 45.4545% | -700% | -900% | -25% | 800% | 233.3333% | 450% | 85.7143% | -350% | 75% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRTS
2026-06-05 20:39:25
Sensus Healthcare (SRTS) has entered into a $15 million revolving credit facility with City National Bank of Florida, according to a recent SEC filing. This financial arrangement provides Sensus Healthcare with access to capital, which can be used for general corporate purposes or to support its operations and growth initiatives. The information was sourced from a Refinitiv report.
2026-06-05 19:39:25
Sensus Healthcare, Inc. (NASDAQ: SRTS) has secured a new $15 million revolving credit facility with City National Bank of Florida, replacing a previous agreement. The loan bears interest at the Secured Overnight Financing Rate plus 3% per annum and matures on June 5, 2027. It is secured by $2.23 million in cash collateral and a security interest in all company assets, and includes strict covenants such as a minimum debt service coverage ratio of 1.50 and requires bank consent for major corporate actions.
2026-06-02 18:40:07
Insiders at Sensus Healthcare, Inc. (NASDAQ:SRTS) who invested US$176.4k in the past year at an average price of US$4.01 per share have seen their investment drop to US$125.4k after an 11% stock decrease. Despite this, insiders have bought shares and not sold any, indicating continued bullishment for the company, with insiders owning 18% of the company worth about US$9.0m.
2026-06-02 12:40:10
Sensus Healthcare (NASDAQ:SRTS) shareholders re-elected Eric Sachetta and Michael J. Sardano as Class II directors and approved executive compensation on a non-binding advisory basis. They also ratified Carr, Riggs & Ingram, LLC as the independent registered public accountant for the fiscal year ending December 31, 2026. The meeting comes as the company's stock is trading near its 52-week low.
2026-06-02 12:40:10
Sensus Healthcare, Inc. (SRTS) announced the results of its 2026 Annual Meeting of Stockholders held on May 29, 2026. Stockholders re-elected Eric Sachetta and Michael J. Sardano as Class II directors, approved the 2025 executive compensation program on a non-binding advisory basis, and ratified the appointment of Carr, Riggs & Ingram, LLC as the independent auditor for 2026. These decisions maintain continuity in the company's leadership, compensation policies, and audit oversight.
2026-06-02 10:40:10
Insiders at Sensus Healthcare, Inc. who bought shares at an average price of US$4.01 over the last year have seen their investment decrease by 11%, now worth US$125.4k, a US$51k loss. Despite this, insiders have bought shares in the last year and last three months, with no selling reported, indicating a bullish outlook. Co-Founder Joseph Sardano made the largest purchase of US$101k at US$4.03 per share, suggesting insiders still see value in the company despite the stock price drop.
